Apr 25,2022

DexCom Showcases Expanded CGM Portfolio at International ATTD Conference, Offering More Choice to People With Diabetes

DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase for the first time its new global portfolio of real-time continuous glucose monitoring (CGM) systems at the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) held April 27-30, 2022 in Barcelona.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Apr 25,2022

Patch Pumps: Periodic Insulin Delivery Patterns

Recent in vitro experiments with patch pumps (PP) Omnipod (OP), Omnipod DASH (OP-D), A6 TouchCare (A6), and Accu-Chek Solo (ACS) have observed periodic fluctuations in the delivered amount of insulin during basal rate and consecutive bolus delivery in some PP, calling for a more systematic characterization of these periodic delivery patterns.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Apr 25,2022

Teladoc Health Names Physician Innovator Dr. Vidya Raman-Tangella as Chief Medical Officer

Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, has named Dr. Vidya Raman-Tangella as chief medical officer to lead enterprise clinical strategy, quality and research.

View Analyst & Ambassador Comments
Go to original news
Apr 25,2022

Analysis of “Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States”

In clinical trials, diabetes technology has shown to improve time in range (TIR) as well as other glucose metrics. In the light of increasing the use of diabetes technology in the T1D population, why do we not see improvement in clinical outcomes?

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Apr 25,2022

In Vitro Continuous 3 Months Operation of Direct Electron Transfer Type Open Circuit Potential Based Glucose Sensor: Heralding the Next CGM Sensor

While continuous glucose monitoring (CGM) systems allow precise and real-time blood glucose control, current electrochemicalbased CGM technologies inherently harbor enzyme instability issues.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 25,2022

Spanish Consensus on the Use of isCGM in the Management of Patients With Insulin Therapy: The MONITOR Project

This consensus aims to evaluate the degree of agreement among Spanish experts on the role of isCGM in the evaluation of glycemic variability, reduction of glycosylated hemoglobin (HbA1c) levels, and selection and adjustment of insulin therapy.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 25,2022

Accuracy of a Seventh-Generation Continuous Glucose Monitoring System in Children and Adolescents With Type 1 Diabetes

Accuracy of a seventh-generation “G7” continuous glucose monitoring (CGM) system was evaluated in children and adolescents with type 1 diabetes (T1D).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 26,2022

Senseonics Holdings, Inc. Schedules First Quarter 2022 Earnings Release and Conference Call for May 10, 2022, at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2022 financial results after market close on Tuesday, May 10, 2022.

View Analyst & Ambassador Comments
Go to original news
Apr 26,2022

Sweetch adds American Diabetes Association exec to its advisory board

Chronic condition therapeutic developer Sweetch announced today that Dr. Robert A. Gabbay has joined the company as an advisor. Gabbay currently serves as the chief scientific and medical officer at the American Diabetes Association, leading the organization’s efforts to drive discovery in diabetes research, care and prevention.

View Analyst & Ambassador Comments
Go to original news
Apr 26,2022

Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop (iDCL) Trial

Researchers investigated the potential benefits of automated insulin delivery (AID) among individuals with type 1 diabetes (T1D) in sub-populations of baseline device use determined by continuous glucose monitor (CGM) use status and insulin delivery via multiple daily injections (MDI) or insulin pump.

CLINICAL STUDY

#cgm

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES